EXSCIENTIA
Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the COVID-19 Therapeutics Accelerator. This is to expedite the optimisation of a new class of COVID-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform to design a novel class of inhibitors targeting the SARS-CoV-2’s main protease enzyme, Mpro , also known as 3CLpro , the causative agent of COVID-19. Mpro is essential for the replication of coronavirus, so administering an Mpro inhibitor to patients as a standalone antiviral or alongside other concurrent treatments could provide a useful frontline therapy.
Exscientia’s AI-based platform will be used to optimise the novel small molecule inhibitors into a therapeutic development candidate, designed to be active against SARS-CoV-2 and other coronaviruses. The project’s goal is to identify potential pan-coronavirus therapeutics that could be effective against COVID-19, and also new mutations or other SARS viruses that may emerge.
The new grant provided by the COVID-19 Therapeutics Accelerator - an initiative launched by the Gates Foundation, Wellcome, and Mastercard to speed up the response to the pandemic - comes in addition to recent backing from the Gates Foundation supporting Exscientia’s work in developing treatments for tuberculosis, malaria and non-hormonal contraceptives which began in January 2021. Under the new grant, Exscientia will receive $1.5 million which will be used to advance a development candidate on achieving defined milestones. The virus protease inhibitors will be designed using Exscientia’s AI-driven drug discovery platform, which delivers optimised compounds, fulfilling complex design goals faster and more effectively than with conventional drug discovery methods.
Dr. Denise Barrault, Senior Portfolio Manager at Exscientia, commented, “The danger of new emerging strains and mutations of coronavirus means there is an urgent need for new antiviral drugs in this pandemic alongside vaccines, to respond more quickly in potential future coronavirus pandemics. We believe that the world needs innovation to accelerate the discovery of more effective counter-measures for a range of infectious diseases, including COVID-19.”
Exscientia has built a track record of improving and accelerating drug discovery by advancing the first three completely AI-designed small molecule drug candidates into clinical trials. In addition to its own proprietary programmes, Exscientia has entered into collaborations with major pharmaceutical companies including Bristol Myers Squibb, Bayer, Sanofi and Dainippon Sumitomo, as well as multiple biotech companies. The company currently has more than 20 partners or wholly owned programmes for diseases involving cancer, immunology, the central nervous system, and genetic mutations.
ENDS
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005344/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EsriIntroduces Latest ArcGIS Integrations for Microsoft Fabric18.11.2025 23:05:00 CET | Press release
Users Can Now Access a Powerful Combination of Spatial Analytics and Intelligent Mapping Esri, the global leader in location intelligence, today announced General Availability of ArcGIS GeoAnalytics for Microsoft Fabric. Also now in public preview is ArcGIS Maps for Microsoft Fabric, a mapping tool enabling users to easily add context with business, lifestyle, demographic, and environmental data to enrich enterprise data in Microsoft OneLake. “This integration makes some of Esri’s core capabilities accessible for data professionals directly from their Microsoft Fabric environment,” said Jack Dangermond, Esri president. “We are pleased to advance our long-standing strategic collaboration with Microsoft to help our shared customers unlock spatial insights and reveal unexplored patterns.” There has been growing market demand among data scientists, data engineers, business analysts, and their executive stakeholders for spatial analytics and mapping. Esri’s GeoAnalytics for Fabric will allo
Andersen Consulting indgår samarbejdsaftale med Business Meets Culture18.11.2025 22:18:00 CET | Pressemeddelelse
Andersen Consulting udvider sin globale rækkevidde gennem en samarbejdsaftale med Business Meets Culture (BMC), der er en global strategikonsulentvirksomhed med lokationer i Latinamerika, Europa og USA. Med afsæt i kulturel intelligens og indsigt i menneskelig adfærd specialiserer BMC sig i strategi, brandstrategi, kommerciel planlægning, innovation og altid transformation. Med deres egne metoder og tværfaglige teams hjælper BMC virksomheder med at knytte strategi tættere til mennesker ved at omsætte udvikling, adfærd og forretningsmæssige udfordringer til relevante muligheder for vækst. Virksomheden samarbejder med førende aktører på tværs af brancher som forbrugsvarer, finansielle tjenester, telekommunikation og teknologi. "Samarbejdet med Andersen Consulting giver os mulighed for at styrke rækkevidden og effekten af vores kulturelt forankrede strategiske arbejde," siger Fernando Parodi, som er CEO for BMC. "Sammen står vi endnu stærkere og kan tilbyde organisationer skarpere perspek
Finalists Announced for 2026 SPIE Startup Challenge, Showcasing Innovative, Investment-Ready Optics and Photonics Technologies and Applications18.11.2025 22:05:00 CET | Press release
The annual pitch competition final will be held at SPIE Photonics West Sevenearly-stage startup companies have been selected to compete for a top prize of $10,000 at the 16th annual SPIE Startup Challenge at Photonics West on 20 January. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118106028/en/ Eventual winner, Trey Daunis of Max-IR Labs, pitches their innovative technology during the 2025 SPIE Startup Challenge, engaging judges and a packed audience at SPIE Photonics West. The SPIE Startup Challenge is a competitive entrepreneurial platform for new businesses that utilize optics and photonics for innovative products or applications. Participating teams are competing for sponsored prizes, in addition to gaining increased visibility with potential investors and exposure to potential collaborators or partners. Cash prizes of $10,000, $5,000, and $2,500, provided by Startup Challenge Founding Partner Jenoptik, will be awa
Owkin Unveils Europe’s First Pan-European Agentic Infrastructure for Biology at the Franco-German Digital Sovereignty Summit18.11.2025 21:48:00 CET | Press release
At today’s Franco-German Summit on Digital Sovereignty in Berlin, Owkin, together with leading academic partners Gustave Roussy (France) and Charité Comprehensive Cancer Center (Germany), announced a landmark initiative to build the first pan-European agentic infrastructure to make biological data AI-ready, as a key step towards biological super intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118529021/en/ Thomas Clozel (CEO of Owkin) joins Emmanuel Macron, Friedrich Merz and others at the Franco-German Digital Sovereignty Summit The project aims to develop and deploy modern AI methods to support biological research and drug development. An initial focus will be on supporting the harmonization and structuring of biomedical data across Europe to enhance scientific collaboration. It will combine agentic AI systems and cutting-edge biomedical data structuring, to power a new reasoning model capable of automating
Reply at Microsoft Ignite 2025: Showcasing AI Innovation, Copilot Experiences, and Intelligent Enterprise Solutions18.11.2025 21:30:00 CET | Press release
Reply [EXM, STAR: REY] is taking part in Microsoft Ignite 2025, a premier event for technology professionals and decision-makers hosted by Microsoft, held from November 18 to 21 in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118836834/en/ A trusted Microsoft partner since 1996, Reply empowers organizations to innovate with Microsoft technologies, driving agility, intelligence, and sustainable growth. A trusted Microsoft partner since 1996, Reply empowers organizations to innovate with Microsoft technologies, driving agility, intelligence, and sustainable growth. With more than 2,000 Microsoft certifications across its network of companies – including Business Elements Reply, Cluster Reply, Solidsoft Reply, Light Reply, Root16 Reply, Valorem Reply, WM Reply and Zest Reply – the group has achieved all six Microsoft Solutions Partner designations. This year, Reply is also celebrating two major h
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom